These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. The cerebrospinal fluid choline levels in patients with Huntington's chorea. Negative effect of haloperidol treatment. Consolo S; Ladinsky H; Bianchi S; Caraceni T Arch Psychiatr Nervenkr (1970); 1977 May; 223(3):265-70. PubMed ID: 142461 [TBL] [Abstract][Full Text] [Related]
29. Reduction of cerebrospinal fluid glutamic acid in Huntington's chorea and in schizophrenic patients. Kim JS; Kornhuber HH; Holzmüller B; Schmid-Burgk W; Mergner T; Krzepinski G Arch Psychiatr Nervenkr (1970); 1980; 228(1):7-10. PubMed ID: 6104477 [TBL] [Abstract][Full Text] [Related]
30. Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment. Wagner L; Björkqvist M; Lundh SH; Wolf R; Börgel A; Schlenzig D; Ludwig HH; Rahfeld JU; Leavitt B; Demuth HU; Petersén Å; von Hörsten S J Neurochem; 2016 Jun; 137(5):820-37. PubMed ID: 27016395 [TBL] [Abstract][Full Text] [Related]
31. In vivo imaging of brain glutamate defects in a knock-in mouse model of Huntington's disease. Pépin J; Francelle L; Carrillo-de Sauvage MA; de Longprez L; Gipchtein P; Cambon K; Valette J; Brouillet E; Flament J Neuroimage; 2016 Oct; 139():53-64. PubMed ID: 27318215 [TBL] [Abstract][Full Text] [Related]
32. Change in the concentrations of amino acids in CSF and serum of patients with essential tremor. Málly J; Baranyi M; Vizi ES J Neural Transm (Vienna); 1996; 103(5):555-60. PubMed ID: 8811501 [TBL] [Abstract][Full Text] [Related]
33. Bioenergetic dysfunction in Huntington's disease human cybrids. Ferreira IL; Cunha-Oliveira T; Nascimento MV; Ribeiro M; Proença MT; Januário C; Oliveira CR; Rego AC Exp Neurol; 2011 Sep; 231(1):127-34. PubMed ID: 21684277 [TBL] [Abstract][Full Text] [Related]
35. Metabolic signatures of Huntington's disease (HD): (1)H NMR analysis of the polar metabolome in post-mortem human brain. Graham SF; Kumar PK; Bjorndahl T; Han B; Yilmaz A; Sherman E; Bahado-Singh RO; Wishart D; Mann D; Green BD Biochim Biophys Acta; 2016 Sep; 1862(9):1675-84. PubMed ID: 27288730 [TBL] [Abstract][Full Text] [Related]
36. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Jenkins BG; Koroshetz WJ; Beal MF; Rosen BR Neurology; 1993 Dec; 43(12):2689-95. PubMed ID: 8255479 [TBL] [Abstract][Full Text] [Related]
37. CSF-protein patterns in extrapyramidal diseases. Preliminary report with special reference to the protein patterns in Huntington's chorea. Kjellin KG; Stibler H Eur Neurol; 1974; 12(3):186-94. PubMed ID: 4139015 [No Abstract] [Full Text] [Related]
38. [Amino acids in the blood in Huntington's chorea]. Oepen H; Oepen I Humangenetik; 1965; 1(3):299-302. PubMed ID: 4223837 [No Abstract] [Full Text] [Related]
39. Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea. Bonnet AM; Tell G; Schechter PJ; Grove J; Saint-Hilaire MH; De Smet Y; Agid Y Mov Disord; 1987; 2(2):117-23. PubMed ID: 2973560 [TBL] [Abstract][Full Text] [Related]
40. Amine metabolites in the cerbrospinal fluid in Huntington's chorea. Curzon G; Gumpert J; Sharpe D J Neurol Neurosurg Psychiatry; 1972 Aug; 35(4):514-9. PubMed ID: 4261957 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]